Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.

Published in:

Cancer (0008543X), 2020, v. 126, n. 24, p. 5247, doi. 10.1002/cncr.33148

By:

• Feldman, Darren R.;
• Ged, Yasser;
• Lee, Chung‐Han;
• Knezevic, Andrea;
• Molina, Ana M.;
• Chen, Ying‐Bei;
• Chaim, Joshua;
• Coskey, Devyn T.;
• Murray, Samuel;
• Tickoo, Satish K.;
• Reuter, Victor E.;
• Patil, Sujata;
• Xiao, Han;
• Aghalar, Jahan;
• Apollo, Arlyn J.;
• Carlo, Maria I.;
• Motzer, Robert J.;
• Voss, Martin H.

Publication type:

Article